Answers are grounded in this paper and cite their sources.
Interstitial fluid plays a vital role in drug delivery and tumour treatment. However, few non-invasive measurement methods are available for measuring low-velocity biological fluid flow. Therefore, this study aimed to develop a novel technology called interstitial flow velocity-MRI. The interstitial flow velocity-MRI sequence consists of a dual inversion recovery preparation and an improved stimulated echo sequence (ISTE) combined with phase-contrast MRI. A homemade flow phantom was used to assess the feasibility and sensitivity of interstitial flow velocity-MRI. In addition, xenografts of female BALB/c mouse models of 4T1 breast cancer administered losartan (40 mg/kg) or saline (n = 6) were subjected to imaging on a 7.0 T scanner to assess the in vivo interstitial fluid flow velocity. The results showed a significant correlation (P < 0.001) between the theoretical velocities and velocities measured using the flow phantom. Interstitial flow velocity-MRI could detect a velocity as low as 10.21 ± 2.65 μm/s with a spatial resolution of 0.313 mm. The losartan group had a lower mean interstitial fluid velocity than the control group (85 ± 16 vs 113 ± 24 μm/s). In addition, compared to the saline treatment, losartan treatment reduced the proportion of collagen fibres by 10% and 12% in the Masson and Sirius red staining groups, respectively. Interstitial flow velocity-MRI has the potential to determine interstitial fluid flow velocity non-invasively and exhibits an intuitive velocity map.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: